Oncogene (1998) 17, 3547 ± 3553 ã 1998 Stockton Press All rights reserved 0950 ± 9232/98 $12.00 http://www.stockton-press.co.uk/onc Keyword Index ± Volume 17

a4 integrin 105 Angiopoietins 1097 BCL6 gene 971 DElk-1 527 Anterior segment dysgenesis 1131 BCL6 mutation 1717 g-irradiation 925 Anti-cancer drugs 1923 BCR 825 1p 2009 Anti-sense cDNA 811 Bcr±Abl 13, 667, 941, 1889, 3073 3'?5' exonuclease 261 Antigen receptors 1353 Bcr/Abl P210 2805 3AB 2819 Antioxidant response element 3145 bHLHZip domain 2463 3q27 translocation 1717 Antisense oligonucleotides 2585 BIR 3247 3T3 cells 3187 Antisense phosphorothioate oligo- Bladder cancer 3021 5' untranslated region 227 deoxynucleotides 455 BLM 2565 5'-CG-3'-rich region in the RET APC 3471 Bloom's syndrome 2565 promoter 2573 AP-1 173, 377, 1131, 1279, 1845 BPV-4 293 5-methylcytosine 1807 AP-2 1261 BRCA1 1681, 1939, 2143, 3115 7q31.2 789 AP-2 transcription factor 1911 BRCA1 1807, 3169 9p21 3021 APO-1 339 BRCA1 interactor 2279 9q22.3 1837 Apoptosis 131, 143, 241, 527, 533, BRCA2 1681, 2377, 2531 10q24-26 1755 545, 643, 691, 867, 901, 999, BRCT domain 2143 16 K protein 1673 1189, 1195, 1207, 1295, 1343, Breast 199, 1681 17p13.3 2095 1439, 1447, 1491, 1503, 1567, Breast cancer 131, 425, 465, 527, 1639, 1653, 1743, 1759, 1813, 577, 727, 919, 1053, 1807, 1877, 1855, 2107, 2115, 2167, 2225, 1939, 2107, 2143, 2235, 2377, Abasic sites 835 2339, 2419, 2515, 2525, 2549, 2711, 2915, 3479, 3499, 3513 Abl 13 2585, 2593, 2629, 2701, 2753, Breast carcinoma 123 abl/myc retrovirus 2125 2811, 2915, 2921, 2943, 2981, Actin 2195 2993, 3055, 3177, 3204, 3215, Actin cytoskeleton 625, 1415 3225, 3237, 3261, 3277, 3301, c-Abl 3309 Activation 1119, 1877 3309, 3319, 3331, 3341, 3351, c-erbB-2 425 Acute myeloid leukemia 699 3359 c-erbB3 1949 Acute promyelocytic leukemia 1759 ASK 3261 c-erbB4 1949 Adapter 1893 Association 3157 c-kit proto-oncogene 795 Adaptor molecule 2393 Astrocytomas 867 c-mos oncogene 1215 Adaptor protein 3073 Ataxia-telangiectasia (AT) 811, c-myc 769, 1503, 3351 Adenovirus 2195 1821, 3301 c-rasHa 35 Adenovirus 5 E1A 2167 ATF2 1483 c-ret 661 Adhesion 913 ATFa 2565 c-Abl 557 Adriamycin (doxorubicin) 131 ATLL 77 c-Fos 327, 2593 AF4/FEL gene 3035 ATM 811, 1821 c-Jun 173, 327, 1483

A¯atoxin B1 3007 Autophosphorylation 1587 c-Met 131, 3045 Akt 313, 1959 Aziridinylbenzoquinones 357 c-Myc 511, 1009, 1491, 1939, 2259, Akt/PKB 1731 3507 Akt/protein kinase B 2811 C. elegans 1109, 3215 Alkyltransferase 845 B lymphocytes 1827 C3 transferase 2195 All-trans-retinoic acid 761 B lymphopoiesis 2955 C3G 2805 ALL-1/MLL/HRX gene 3035 B-Myb 2679 CaaX box 1797 Allele-speci®c inactivation 105 Baculo-virus system 2645 Caco-2 cells 877 Allelic duplication 733 BAD 2419 CAK kinase 2733 Allelic expression 1739 Bak 2943 Calcineurin 1235 Allelic loss 1979 bak 2585 Calcium ionophore 527 ALT pathway 709 Bax 999, 2993, 3225, 3341, 3401 Calcium-binding protein 465 Alternative promoter 1149 BAX 2003 Calpain 1069 Alternative spliced p53 2333 Bax cleavage 1069 cAMP 387, 631, 3015 Alternative splicing 1019, 1149, Bc12 1855 Cancer 419, 981, 2619, 2719, 3455, 3513 Bcl-2 187, 1235, 1903, 2107, 2225, 3471 Alternative translation initiation 2549, 2889, 3225, 3237, 3341, Cancer models 3385 981 3401 Carcinogenesis 25, 3417 AML1 2287 bcl-2 proteins 3207 Carcinoma in situ 123 AML1/PEBP2aB/CBFA2 1813 BCL-6 2473 CARD 3247

Amplicon organization 2771 Bcl-XL 1295 Caspase 1639, 2107, 2549, 2629,

Ampli®cation 339, 2313 bcl-xL 2585 3237, 3247 Anchorage 1271 Bcl-X 2981 Caspase 3 931, 1295 Androgen 2619 BCL2 1223 Caspase cascade 2555 Angiogenesis 227, 303, 819 BCL2 gene 971 Caspases 2515, 2753, 3207 Keyword Index ± Volume 17

3548 Castration 2593 Chromosomal translocation Death domain 3261 Cathepsin D 3331 t(4;11) 3035 Death receptors 3207 Caudal 657 Chromosomal translocation 503, Degradation 2437, 2933 CD40 2383 2799, 3199 Deletion 475 CD54 2383 Chromosome 1 3513 Dermato®brosarcoma 1313 CD95 339, 3271 Chromosome 3p 2359 Detoxifying enzyme genes 3145 CD95 ligand 2323 Chromosome 9p21 2669 Development regulation 1911 CD95/APO-1/Fas 2811 Chromosome 10 123, 1749 Deviation 3271 Cdc2 673 Chromosome 10q23 1557 DHPLC 475 CDC25A 1969 Chromosome 11p15 237 Di€erential display PCR 1287 CDK 2787, 3093, 3365 Chromosome 18p 3499 Di€erentiation 367, 425, 585, 761, Cdk inhibitor 3445 Chromosome translocation 2873 1119, 1663, 1759, 2047, 2367, cdk(s) 631 Chronic myeloid leukaemia 667 2495, 3083, 3435 cdk2 1491 chTRF1 2137 Dimerization 3199 CDK2 2637 cip1/waf1/sdi1 2827 Distal chromosome 4 region 925 Cdk2 2679 Cipro®brate 1039 DMBT 1755 Cdk3 2259 CIR1 1321 DMSO 1159 CDK4 2961 Cisplatin 387, 2235, 2339 DNA 2743 CDKN2 2779 CK2 13, 1045 DNA binding 651 CDKs 1159, 2393 CKI 631, 3365 DNA damage 781, 2555, 3301, cDNA subtraction 503 CKIs 2393 3309 CDX2 657 Cloning 1245 DNA methylation 557, 3021, 3169 ceBNIP3 2525 CML 825, 941 DNA polymerase 2827 ced genes 3215 Colorectal cancer 157, 657, 719, DNA polymerases 835 CED-3 2525 999, 2003, 2009 DNA repair 401, 533, 545, 835, CED-9 2525 Colorectal carcinoma 1931 845, 1577, 3177 Cell adhesion 1365, 1439, 2863, Connexins 1673 DNA replication ®delity 261 3427 Cooperativity 347 DNA synthesis 889, 1777 Cell and tissue di€erentiation 1027 Cowden syndrome 727 DNA vaccination 3125 Cell cycle 611, 673, 751, 811, 867, CpG island 577, 1807 DOC-2 419 949, 1027, 1159, 1271, 1457, CREM 3015 Dormancy 819 1549, 1567, 1777, 1827, 2039, Crk 1893 Dorsalization 1509 2177, 2259, 2377, 2393, 2619, Crk1 2805 Down-regulation 1743 2981, 3177, 3287, 3301, 3359, CRKL 1893 Doxorubicin 2235 3365 CROC1 1321 DRB 1045 Cell cycle arrest 1691 CSF1 1287 Drosophila 1911 Cell cycle control 1491, 3103 Csk 1587 Drosophila 3215 Cell death 1475, 2889, 3237, 3401, CTD phosphorylation 2733 Drug resistance 2419 3507 Curcumin 173 Drug-induced apoptosis 1069 Cell di€erentiation 2901 Cyclin 959 Ductin 1673 Cell growth 1331, 2701 Cyclin A 293, 2679 DUTT1/Hrobo-1 1723 Cell hybrids 709 Cyclin A-associated kinase 293 Dysplasia 1837 Cell proliferation 433, 481, 1039, Cyclin D1 1053, 1271, 2313 Dysregulated expression 2313 1949, 2463, 3103 Cyclin D2 1159 Cell scattering 57 Cyclin D3 1027 Cell signaling 173 Cyclin dependent kinase 959, 1691, E-box binding protein 1009 Cell survival 1365 3083 E1B 19K 2993 Cell transformation 293, 1447, Cyclin dependent kinase 2 2973 E2-C 2039 1673, 2787, 2901 Cyclin E 2637 E2F 143, 585, 1777, 2177, 2259, Cell-cycle 2251, 3287 Cyclin E2 2637, 2787 3463 Cell-cycle regulation 2669 Cyclin H 2733 E2F binding protein 853 Cell-substrate interaction 271 Cyclin-dependent kinase activity E2F-1 545 Cellular transformation 1305 2295 E2F-4 545 Centrosome 35 Cyclin-dependent kinases 2437 E2F-6 611 Ceramide 3277 Cyclins 631, 2251, 2393, 3365 E2F-dependent transcription 853 Ceramides 1855 Cyclophilin 1019 E2F-family 867 Cervical carcinoma 1195 Cytochrome 2515 E6-AP 2933 CGH 2403 Cytochrome c 2753, 3401 E8 293 Checkpoint 673 Cytokines 339 Early development 3427 Checkpoint control 2177 Cytoskeleton 271, 1245, 1343, 1797 EB1 3471 Chemoresistance 3225 EBV 1607, 1827 Chemotaxis 283 EC cells 2495 Chemotherapy 1089, 1567, 2585 Dab2 419 E€ector 1395 Chernobyl 1983 DAP-kinase 3331 E€ectors 1415 Chimeric gene 699 DAXX 3261 EGF 1279, 1539 Chromatin 413 DDRT 1245 EGF-receptor 19 Keyword Index ± Volume 17

3549 EGFR 1949 Fetal lung 493 Genomic structure 3065 egr1 2495 FGF 1279, 1663, 2155 Genotype 1061 eIF-4G 769 FGF receptor 283 Germline mutation 733 eIF4G/initiation factors 2921 FGF-3 2059 Gestation stage 493 Elk-1 527 FGF-4 2059 GFP-fusion protein 2645 Emodin 913 Fgf8 2711 GL331 2225 EMS1 1053 FGF8 2711 Glioblastoma 2973, 3499 Endocrine response 1949 FHIT 83 Glioma 1567, 1755, 2323, 2873 Endocrine therapy 2619 Fiber-FISH 2771 Glycophorin 1009 Endometrial carcinoma 2413 Fibroblast Growth Factor 2711 Glycosylation 2087 Endoplasmic reticulum calcium Fibroblast growth factor 67 Glycosyltransferase 2087 pump 1903 Fibroblast growth factor receptor GRB-IR 3065 Endoreduplication 1691 67 Grb2 1079 Endothelial cells 913, 1097 Fibroblast growth factor-4 761 Grb10 941 env-pX transgenic rat 2955 Fibronectin 1179 GRB10 3065 Eph 1509 FIN-1 1279 Green ¯uorescent protein 1797 Eph-related kinases 255 FISH 2313 Growth arrest 3309, 3319 Ephrin 521, 1509 Fli-1 1149 Growth control 25 Epidermal di€erentiation 949 Fli-1b 1149 Growth factor receptor 999 Epidermis 303 Flp site-speci®c DNA recombina- Growth factors 795 Epithelia 3435 tion 1 Growth inhibition 1089 Epithelial cancer 2883 Focal adhesion complexes 1365 Growth pattern 2655 Epithelial cells 187, 2719 fos 3319 Growth suppression 3204 Epithelio-mesenchymal conversion Four hBAG-1 isoforms 981 GTPases 1329 67 fra2 1131 Epitope mapping 3125 fra-1 377 Epstein±Barr virus 2383 FRA7G 789 Hamster 3417 ER 1949 Fractional allelic loss 2655 Ha-ras 877 erbB-2 receptor 3177 Functional conservation 1911 HBP1 3463 erbB-4 919 Functional diversity 521 HEK2 255 erbB2 2719 Functional gene cloning 3331 Helicase 2565 ERK 1383, 1447 Functional genomics 3287 Hematopoiesis 2287, 2955 Erk 1705 Fungal metabolite 1503 Hepatic ®brosis 115 ERK2 3157 Hepatic stellate cells 115 ERRa 2429 Hepatic tumour 1253 Erythroleukemia 1119 G-protein 1375 Hepatitis B virus 2115 ES cell di€erentiation 433 G-protein coupled receptors 1331, Hepatocellular carcinoma 3007 Estrogen receptor 557 1617 Hepatocyte growth factor 481, Estrogens 425 G proteins 1329, 1331, 1383 3045

Etoposide 387 G1 arrest 1549 Hepatocyte growth factor (HGF)

ETS 2883 G2/M 2743 131 ETS1 1517 G-CSF receptor 503 HepG2 cell 931 ETS-domain 93 G1 arrest 3137 HER-2/neu 2235 Ewing tumors 603 G1 cell cycle control 2787 HER-2/Neu/ErbB-2 1877 Ewing's sarcoma 2039 G1/S transition 1027 Heregulin 2107 EWS/FLI1 2039 G2 673 HGF 57, 1179 Exon-missing 801 gadd45 959 HGF-antagonist 3045 Expression genetics 1305 gadd45 2149 HGF/SF 2019 Extended life 199 gadd153 959 Hirschsprung disease 2851, 3065 Extended life span 1207 Gap junction 1673 Histone acetyltransferase 557, 2531 Extracellular signal-regulated gas1 1629 Histone phosphorylation 2645 kinase 1223 Gastric carcinoma 2655 HIV 3093 Gene ampli®cation 1019, 2403 HL-60 cells 1069, 2211 Gene expression 241, 901, 1903 HL60 chimeric amplicon 2771 FADD 3261 Gene induction 481 HNPCC 157 Familial 1681 Gene rearrangement 1313 hnRNP-K 1597 Familial cancer 1061 Gene rearrangements 2873 Homozygous deletion 1557, 1979 Familial non-speci®c dementia Gene targeting 1375, 2287, 3427 HOX11 promoter 1787 1723 Gene transcription 511 HPK1 1893 FAP 2009 Genetic code 1469 HPV 781, 2943 FAS 339 Genetic predisposition 727 HPV 16 E7 631 Fas 2549 Genetic reactivation 401 HPV E6 and E7 oncogenes 1207 fas 2585 Genomic DNA 2761 HPV E7 protein 2027 Fas-ligand 1813 Genomic footprinting 585 HSCR patients 2573 Fas-mediated apoptosis 931 Genomic instability 35, 719, 1931, HTLV-1 77, 2955 FasL 1503 1983, 3455 Human 179, 2761 Keyword Index ± Volume 17

3550 Human breast cancers 3169 JNK 173, 213, 1383, 1447, 3261, Mammary involution 2305 Human chromosome 10 2873 3277 Mammary tumorigenesis 2711 Human EC cells 853 Jun 3145 Mammary tumors 2059 Human embryonal carcinomas 761 MAP kinase 1271, 1447, 1845, Human papillomavirus 1195 2403 HVJ-liposome 455 K-ras 493 MAP kinase kinase (MKK) 19 Hypermethylation 2413 K-ras p21 493 MAP kinase signaling pathway 57 Hyperplasia 1173 K12 2981 MAP kinases 1331, 3493 Hypoxia 2295, 2333, 3341, 3401 Karyotype instability 719 MAPK 213, 2155 Keratinocyte 1195, 3083 Mapping 3065 Keratin 2901 Matrix degradation 1989 IkBa 913, 1607, 1821 KGF 1279 MAX 1109 IAP 3247 KHS 1893 MBPs binding domain 801 ICER-IIg 3015 Ki-ras 2403 MCF-7 527 Identity 2137 Kidney 661 MCL1 1223 IGF-II 1261, 1295 Kinase 441, 1893 mdm-2 781 IGF-II gene 877 Kinases 1329 MDM2 643, 2629 IL-1 1295 Kip1 2701 Mdm2 2543 IL-2 1235 KIR 2535 Medulloblastoma 1663 IL-4 1235 KIT 1653 MEK 1447 IL-6 1039 Knockout mice 3385 Mek 2047 IL-7 signal transduction 2125 KRAB 2013 MEK inhibitor 57 Illegitimate recombination 2771 Krox24 2495 MEKK 1447 ILP 931 MEN 2 2851 Immortal 199 Menin 2485 Immortalization 1321, 3417 L-myc 1019 Merlin 2195 Immune 3271 LacSwitch 2839 Mesoderm induction 2155 Immune responses 3125 Latrophilin 3513 Met 1179, 2019, 2691 Immunocytochemistry 699 Leucine-rich repeat 2873 MET tyrosine kinase 733 Immunohistochemistry 2313 Leukaemia 2799, 3199 Metalloproteinase 481 Immunotherapy 3125 Leukemia 503 Metastasis 105, 465, 741, 1989, Imprinting 1739 Leukemogenesis 77 2019, 2601, 3331 in situ hybridization 1577 Li±Fraumeni syndrome 533, 643, Methoxyestradiol 241 Indolent B cell lymphoma 2073 651, 1061 Methylation 2779, 3137 Inducible p53 1923 LIM domains 2799 MGMT 845 Inducible response 845 Lipoma 413 Mice 2305, 2761 Inducible vector 3187 LIR-1 2535 Microsatellite instability 157, 657, Inheritied cancer syndromes 3385 Liver 1039, 2115 2003, 2413 Inhibition of DNA synthesis 2027 LMP-1 2383 Microinjection 889 Inhibitor 611 Localization 2137 Microsatellites 925, 1983 Inhibitor of apoptosis 3247 LOH 789, 1749, 2095, 2719, 3029 Microtubules 3471 Initiation of protein synthesis 2921 LOH 7p 395 Middle T antigen 565, 1797 Insulin 1959 Loss of heterozygosity 123, 207, Min 2009 Insulin/IGF-1 889 237, 449, 925, 1185, 1557, 1837, Minisatellites 1983 Integration 2457 2101, 2359, 2655, 3499 Mismatch repair 157 Integrin 1463, 2805 Lovastatin 2393 Mitochondria 1639, 1653, 2525 Integrin b1, b4 187 Lung 1743 Mitochondrial DNA 1931 Integrins 271, 1365 Lung cancer 241, 449, 475, 901, Mitochondrial membrane potential Interferon g 2973, 3331 1723, 2095, 3029 2993 Interleukin 2 2609 Lung tumor 493 Mitochondrial membranes 1069 Interleukin 6 2271 Lymphoblastoid cell lines 2339 Mitogen activated protein kinase Interleukin-1 1195 Lymphoma 1245, 1705 1223 Internal ribosome entry site (IRES) Mitosis 3471 227 MKK 1447 Intestinal epithial cells 47 Macrophage 2535 MLH1 2413 Intron/exon structure 1871 Macrophages 387 Molecular modelling 2463 Inverted and direct repeats 2771 MAD 1109 Mom1 2009 Ionizing radiation 1821, 2961 Maf 247 Monoclonal antibody 2235 IRF-1 3319 Malignant melanoma 1885 mot-2 protein 907 Isoform 2629 Malignant transformation 907 Motility 3427 Mammalian CDC6 1777 Mouse mammary tumor virus 1577 Mammalian cell cycle 2295 Mouse model 1625 JAK 2271 Mammary carcinogenesis 1173 Mouse model for sporadic cancer 1 JAK-STAT 1483 Mammary epithelium 1173 Mouse RNA in situ hybridization JAK-STAT signaling 2125 Mammary gland 2761 2485 JAK/STAT linked receptor 1617 Mammary gland tumor 2403 Mouse thymic lymphomas 925 Keyword Index ± Volume 17

3551 mRNA 3169 Nuclear factor of activated T cells p53 143, 261, 347, 357, 387, 401, mSos 19 2609 533, 557, 643, 651, 673, 709, MTAP 2669 Nuclear micro-injection 801 719, 781, 845, 959, 1045, 1089, Multiple endocrine neoplasia Nuclear receptors 2429 1119, 1207, 1253, 1483, 1577, type 1 2485 Nuclear targeting 2645 1625, 1653, 1681, 1837, 1855, Murine erythroleukemia cells Nucleophosmin/B23 3055 2003, 2095, 2115, 2323, 2351, 1009 Nucleotide excision 261 2543, 2629, 2733, 2743, 2779, Murine melanoma 2167 Nucleotide excision repair 2827 2889, 2933, 2961, 3115, 3287, Muscle creatine kinase gene 347 3507 Muscle di€erentiation 347 p53 mutants 35 Mutated p53 2339 Oesophageal cancer 2101 p53 mutation 2333 Mutation 475, 493, 1681, 1755, Oligomerization 651, 2351 p53 tumour suppressor 2445 1979, 2279 Oligomerization domain 643 p53 241, 901, 2305, 2819 Mutation analysis 157 Onco-protein 1149 p53 gene 3007 Mutation detection 3065 Oncogene 247, 413, 425, 1079, p70 S6 kinase 19 Mutations 1167 1383, 1447, 1539, 2087, 2187, p73 1739 Mutator phenotype 3455 2505, 2629, 2691, 2883 p75NGFR 187 Myc 165, 2463 Oncogene cooperation 2661 p96 1173 myc 2149 Oncogenes 339, 1329, 2901 p120RasGAP 271 MYC ampli®cation 2771 Oncogenesis 165, 1189, 2711 p190RhoGAP 271 Myc/Max DNA-binding 511 Oncogenic signalling 1305 p210bcr-abl oncoprotein 825 MyD genes 3319 Oocyte maturation 1215 p300 1253 Myeloid cells 2701 Osteoclastogenesis 2955 Paclitaxel 2419 Myeloid di€erentiation 3319 Osteogenesis 1517 Pancreatic cancer 1969 Myeloid leukemia 1527 Osteopontin 1517 Papillary renal cell tumours 733 MyoD 347 Osteosarcoma 2457 Papilloma 2251 Myoepithelial cells 2059 Ovarian 2359 PARP 2819 Ovarian adenocarcinomas PCNA 2437, 2827 1185 PCR 3169 N-myc 2073 Ovarian cancer 207, 2235, 2419 PDGF 313 N-CoR 2473 Ovarian carcinoma 2839 PDGF-R 1463 N-ethylnitrosourea 493 Overexpression 981 PDGFB gene 1313 N-Ras proto-oncogene 1705 Oxygen 1653 PEA3 93 NAIP 3247 PEBP2aA/CBFA1 1517 Necrosis 2515, 2753, 3341 PEBP2b/CBFb 2287 Negative element 1787 P/CAF 2531 PEBP2b/CBFb 699 Neoplasia 819 p9Ka 465 Perinuclear 565 Neoplastic transformation 3493 p15 595, 1969 Peripheral blood lymphocytes 3093 neu/her-2 2087 p15INK4B 1549 PH domain 313 Neuroblastoma 751, 2367, 3137 p16 595, 867, 3137 Phenotype 1061 Neurodevelopment 521 p16INK4a 199 Phosphatase 441 Neuro®bromatosis 795 p16INK4A 2669 Phosphatidylinositol anchor 1989 Neuron 179 p16/p19, deletion 3021 Phosphatidylinositol 3-kinase 691, Neuroretina 247 p16INK4a/p16a 2779 919 NF kappa B 2609 p19ARF/p16b 2779 Phosphocholine NFkB 1483 p21 357, 751, 1119, 2743, 2961, phosphatidylcholine 1845 NF-kB 173, 685, 913, 1607, 2383, 3463 Phosphoinositide 3-kinase 1343 3247, 3261 p21WAF1 apoptosis 2305 Phosphorylation 673, 1045, 1877, NF-kB-a 1821 p21Cip/Waf1 1271 2177, 2679, 2933, 3157 NF-AT 1235 p21Cip1 47 Phosphotyrosine 1469 NF-E2 related factors 3145 p21CIP1 1159 PI 3-kinase 313, 1629, 1959 NF1 1705 p21WAF1 199, 533, 931 Pigmentation 2601 NF2 gene 801 p21Waf1 959 PIR-B 2535 NGF 691 p21waf1 545, 1923 PITALRE 3093 NHL 1717 p21Waf1/Cip1 1691 Pituitary gland tumor 1 NIH3T3 907 p21WAF1/CIP1 2973 PKB 313, 691 Nitric oxide 2323 p21WAF1/CIP1/SDI1 781 PKC 877, 1539 Nocodazole 2743 p21WAF1/Cip1/Sdi1 1549 PLA2G2A 2009 Non-Hodgkin's lymphoma 971 p21cip1 protein induction 2027 PML/RARa 1759 Non-small cell lung cancer 1141, p21Cip1 2437 Poly(ADP-ribose)polymerase 2225 2669, 3499 p21ras 1731, 1769 Polyoma middle T 877 Non-small cell lung carcinoma p27 2259 Polyomavirus 565 2779 p27Kip1 47, 293, 959, 1159, 1549, Polyproline 1469 Non-steroidal anti-in¯ammatory 1827, 2637, 3083 Post-transcription regulation 2027 drugs 1769 p27Kip1 Cdk inhibitor 2619 Post-translational processing 2211 Normal development 1189 p34cdc2 kinase 3103 POZ domain 2473 Keyword Index ± Volume 17

3552 pRb 1253, 1271 RAR 2839 S phase checkpoint 3083 pRB 2177, 2295 RAS 1305 S6 kinase 769 Pre-B lymphomagenesis 2125 Ras 691, 991, 1331, 1383, 1395, S100A4 465 Primary keratinocytes 1207 1457, 1539, 2019, 2047, 2863 SAP kinase 1889 Progesterone receptor 557 ras 1617, 2701 Sarcoma 2013 Progestin 3479 Ras, cell cycle 47 Scatter factor (SF) 131 Prognosis 751, 1053, 3137 Ras sub-family 1395 Schwann cells 795 Prognostic factors 3169 Ras superfamily 1415 Schwannomin 2195 Programmed cell death 557, 2981, Ras-bound GTP and GDP 2403 SCLC 1749 3215, 3247 Ras-GTPase 1705 Secondary axis 1509 Proliferation 425, 1629, 1663, 3351 Rat 1989 Secretion 1089

Promoter 1777 Rat-1 527 Secretory phospholipase A2 2009 Promoter methylation 3445 RB 1625 Senescence 595, 709, 1691, 1923, Promoter sequence 1871 Rb 3187 3417 Prostaglandin A2 959 Rb inactivation 1 Serine/threonine kinase 2645 Prostate 2593 RDA 2039 Serine protease 3507 Prostate cancer 1549, 1979, 2883, Reactive oxygen species 2515, SH2 941 2889, 3125 2753 SH2 domain 441, 3073 Protease 3237 Receptor 25 SH2-domains 255 Proteasome 327, 2889 Receptor tyrosine kinase 919, SH2/SH3 adapters 2155 Protein dimerization 2463 1079, 1097 SH3 1597, 1893 Protein interactions 2799 Receptor tyrosine kinases 115 SH3 domain 3073 Protein kinase 313 Receptors 1329 Shc 3073 Protein kinase A translation 1215 Recombination 3035, 3309 shc 565 Protein modules 1469 Regulation 2271 SHP-1 2535 Protein motifs 1469 Regulation of expression 3145 SHPTP1 1889 Protein phosphatase type 1 (PP1) Regulation of protein Sigma factors 603 2295 ubiquitination 1483 Signal transduction 13, 255, 433, Protein prenylation 1439 Renal cell carcinoma 1739 441, 625, 741, 919, 941, 991, Protein stability 1483 Reoxygenation 3341, 3401 1097, 1329, 1353, 1395, 1415, Protein truncation test (PTT) 801 Repression 2505, 3157 1439, 1447, 1475, 1483, 1663, Protein tyrosine kinases 1353 Repressor 1787 2819, 3207 Protein tyrosine phosphatase 1B RER 719 Signaling 1383, 2691 1587 Resistance 387 Signalling pathways 1731 Protein±protein interaction 511 RET 367 Silencing 1787 Proteolysis 213 RET 661 Single-chain antibody 2445 Proto-oncogene c-myc 2811 Ret 1079, 1625, 1885 Sinusoidal endothelium 115 PSA 3125 RET protooncogene promoter Skin 25 Pseudogene 2761 2573 Skin carcinogenesis 303 PTCH 1167 RET receptor 2851 Skin, chemical carcinogenesis 35 PTEN 123, 1755 RET receptor tyrosine kinase 3065 Smad 1743 PTEN/MMAC1 475, 727 Retina 585 Smad2 1969 PTEN/MMAC1 1979 Retinal pigment epithelium 2601 Smad4 1969 PTP 2535 Retinoblastoma 557 Small cell lung cancer 1019 PTTG 2187 Retinoblastoma family 949 Small G-proteins 991 PU.1 2287 Retinoblastoma protein 2177, SMRT 2473 Pulmonary adenoma 3029 3445 SnoN 2505 Retinoic acid 1759, 1827 Sp1 877, 3463 Retinoic acid receptor beta 751 spcDNA 3455 Quiescence 1491 Retinoids 2839 Splicing switch 67 Quinones 357 Retroviral insertion 2073 Squamous carcinogenesis 83 Review 1395 Squamous cell carcinoma 1837, Rho 1331, 2195, 2863 2251 rac 1617 Rho A GTPase 991 Squamous metaplasia 3021 Rac 2047, 2195 Rho family small GTP binding Src 1463, 1539 Rac1 3427 protein 625 Src and Yes regulation 1587 Radiation 1089, 1983, 3359 Rho proteins 1855 SSX 2013 Radiation sensitivity and Rho-kinase 2863 Stability 2543 chromosome abnormality 3115 RING domain 2143 STAT 2271 Radiosensitivity 811 RING ®nger 3247 Stat3 transactivation 3157 Radiosensitization 3359 RNA polymerase II 3093 Steel 1653 Raf 19, 685, 1457, 1539 ron 741 Stem cell factor 795 raf-1 367 ROS 1639 Stem cell line 667 raf/myc retrovirus 2125 RT±PCR 83, 1949, 2287 Stem cells 1663 Rap 1A 2211 RXR 2839 Steroid 1567 Rapamycin 769 Ryk 3435 Stimulation for growth 327 Keyword Index ± Volume 17

3553 Stress 19, 3277 Transcription 585, 603, 1089, 1279, Tumorigenesis di€erential display Stress ®bers 699, 991 1787, 1939, 2013, 2187, 2279, 1321 Stress kinase pathway 685 2351, 2505, 2719, 3199 Tumorigenicity 761 Stress kinases 1483 Transcription factor 247, 699, Tumour 1681 Stress response 3287 1527, 1813, 2287, 2719, 2883 Tumours 3199 Stretch-activated ion channel Transcription factor AP-1 2593, Tumour suppressor 1755 455 2901 Tumour suppressor gene 207, Subcellular localization 981 Transcription factor cross-talk 1185, 1723 Sulindac 1769 2429 Two dimensional electrophoresis Survivin 3247 Transcription factors 93, 2495, 3455 SV40 2457 3493 Two-hydrid-system 603 SV40 large T-antigen 1253 Transcriptional activation 347, Tylosis 2101 Syndecan-1 1279 401 Tyrosinase 2601 Synergistic transactivation 1517 Transcriptional activator 1149 Tyrosine kinase 557, 741, 941, Transcriptional regulation 2679, 1463, 2271, 2851, 3435 3365 Tyrosine kinase linked receptor T cell 2799 Transcriptional repression 2149, 1617 T cell hybridoma 1503 2473 Tyrosine phosphatase 433 T cells 1731, 3271 Transcriptional target 1305 T lymphocyte 1813 Transformation 377, 511, 565, t(2;18)(p11;q21) 971 603, 991, 1313, 1439, 1889, 1939, U2020 deletion 1723 t(3;16)(q27;p11.2) 971 2039, 2047, 2505 Ubiquitin 327, 2943 T-lymphocytes 595 Transforming growth factor-alpha Ubiquitination 2543, 3479 Target gene 1527 (TGFa) 1877 UEV-1 1321 Target genes 165 Transgenic 1131 Uni-axial cyclic stretch 455 Tat 3093 Transgenic mice 143, 303, 1253, Urokinase receptor 213 TCPOBOP 1039 1577, 1877, 2403, 2601 UV 533, 2555, 2933 Tek/Tie2 1097 Transgenic mouse 1375, 1885 UV irradiation 1045, 1845 Telomerase 3417 Transitional cell carcinoma of the Telomerase activity 3055 bladder 1167 Telomerase regulation 187 Translation 769 v-Src 1629 Telomere 901, 3417 Translational regulation 227 Vascular endothelial growth factor Telomeres 709, 3455 Translocation 1149 (VEGF) 227 Teratocarcinoma 179 Transmembrane signalling 1375 vav 1597 Testis 143 Trk 691 Viral tumour antigens 545 Tetracycline 1491 TrkA 2367 Tetramerization 825 TrkC gene 1871 TFIIH 2733 Trophoblastic diseases 419 WAF1 2819 TGFb 25, 47, 1179, 1549, 1743 TRP-1 2601 Westerns 83 TGFb-RII 1969 TSG101 protein 2761 Wilms tumor 237 TGF-b-induced apoptosis 1959 TSP/HAM 77 Wilms Tumour 395, 1287 Thyroid 631, 2047 Tumor 413 Wnt-13 179 Thyroid cancer 789, 1625 Tumor cell line 1019 WT tumour suppressor gene Thyroid carcinomas 377 Tumor cells 1261 7p 21-15 395 Thyroid hormone 2429 Tumor genetics 449 WT1 1287 Thyroid tumors 1983 Tumor invasion 3045 TIMP-3 481 Tumor progression 1, 2073, 2251, Tissue-speci®c 1 2333 X protein 2115 tms1 2733 Tumor promotion 3493 X-rays 3359 TNF 913, 1039 Tumor suppression 2167 TNFa 1607, 1855, 2555 Tumor suppressor 419, 1141, 1749, TNFR 3261 1807, 2143, 2279, 2359, 2629, Yeast truncation assay 727 TNF-R 2383 3015, 3479 Yeast two-hybrid 941 TOR 769 Tumor suppressors 3385 YY-1 1009 TP53 1061 Tumor suppressor gene 2095, YY1 511 TPA 2915 2377, 2873, 3029 Tpl-2 2609 Tumor suppressor genes 237, TRADD 3261 925 Zebra®sh 93 TRAF 3261 Tumor-stromal interactions 3045 Zinc ®nger 2661 Transactivation 643, 2445, Tumorigenesis 741, 2019, 2187, Zinc ®nger protein 1287 2743 2313, 3351 Zyxin 1597